At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 31 enrolled
Drug / intervention
Emdogain® +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study.
In Brief
A Phase 4 clinical trial evaluating Emdogain® and Surgery alone for Failure of Dental Implant Due to Infection and 8 related conditions. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate if surgical treatment of peri-implantitis with enamel matrix derivative (Emdogain®, EMD) will have an additional effect on the healing outcome, changes in the peri-implant microflora and on the inflammatory response in the periimplant pocket at 12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFailure of Dental Implant Due to Infection, Infection, Inflammation, Peri-implantitis, Bacterial Infections, Bleeding of Subgingival Space, Molecular Sequence Variation, Periodontal Diseases, Mouth Diseases
CountriesSweden
CollaboratorsUmeå University
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
Primary CompletionJan 2014
First PostedJul 2015
TodayJul 2026
First PostedJul 16, 2015
Enrollment StartDec 1, 2008
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 11.0 years ago
Interventions
Emdogain®device
Surgery and Emdogain®
Surgery alonedevice
Surgery alone